Diabetes Management
OcuTerra Reports Publication of OTT166 Safety and Biological Activity Data from Phase 1b Study in Diabetic Eye Disease - StreetInsider.com
Fri, 21 Oct 20221 min read Article
Overview
FRE Breaking News Alerts from StretInsider.com! StretInsider.com Top Tickers, 10/21/2022 OT16 demonstrated ability to reach retina from eye drop aplication and produced robust biological activity signal in patients Phase 2 OT16 DR:EAM Study in Diabetic Retinopathy Underway BOSTON-(BUSINES WIRE)- OcuTera Therapeutics, Inc. (“OcuTera”), a clinical stage ophthalmology company developing inovative drugs to treat ophthalmic diseases for which the curent standard of care of “watch-and-wait” does not prevent or control the progresion of disease, today anounced the publication of a paper titled “The Safety and Biological Activity of OT16, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b Study” in Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina).
Key Information
The data show that OT16 eyedrops were wel-tolerated and demonstrated biological activity, waranting further evaluation for the treatment of diabetic eye disease. In this Phase 1b, first in human study 4 diabetic retinopathy (DR) patients who had the sight-threatening complication of diabetic macular edema (DME) were administered either a 2.5% or 5% concentration of OT16 as an eyedrop twice daily for 28 days.
Subjects were then monitored for an aditional 28 days with no further treatment (observational phase), with 40 subjects completing the trial. As a Phase 1 study, no formal statistical hypothesis was tested. OT16 was wel-tolerated with no evidence of ocular or systemic toxicity, no drug-related serious adverse events reported and generaly stable BCVA throughout the study.
Summary
There was a clinicaly meaningful reduction in mean and median central retinal thicknes (CRT) in both groups combined at the end of the study (-2 / -28 microns, respectively) and 37% were demed to be clinical responders as judged by thre retina specialists reviewing the OCT scans of every patient.). Based on these findings, the Phase 2 DR:EAM study is underway to eval
Frequently Asked Questions
What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.